Studies on the extended spectrum beta lactamases activity in isolates from diabetes patients
© Kalyani et al; licensee BioMed Central Ltd. 2012
Published: 4 May 2012
Extended spectrum beta-lactamases (ESBLs) are enzymes produced by some gram negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam. ESBLs are commonly recognized in a variety of Enterobacteriaceae and Pseudomonas aeruginosa isolates. This study focused on the prevalence of ESBL producing strains from diabetes patients and their antimicrobial correlation.
ESBL activity studied in different gram negative bacteria isolated from xxx urine samples were subjected to antimicrobial susceptibility testing by Kirby-Bauer method as per CLSI guidelines antimicrobials agents (Cefpodoxime, Ceftazidime, Cefotaxime, & Ceftriaxone) selected for testing along with combinations of antimicrobials Cefoperazone sulbactam (CFS), Piperacillin-tazobactam (PT) Amoxyclav (AC) were compared for their ability to detect ESBL producers phenotypically.
Among 4446 samples processed 3426 showed ESBL activity in different gram negative bacilli 85% in E.coli, 7% Klebsiella pneumoniae, 0.5% Klebsiella oxytoca, 2.3% Pseudomonas aeruginosa, 0 .5% Citrobacter koseri, 1% in Proteus mirabilis.
There is a significant increase in the prevalence of ESBL E.coli when compared to other gram negative isolates. Detection of ESBL by phenotypic method in the absence of molecular testing is considered as timely, affordable and appropriate measure in deciding the antibiotic therapy.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.